Its modelling suggests 5 million UK working-age adults could fall short on selenium, potassium and iron if GLP-1 use hits 15% and crop nutrients keep falling.
Recap by typeshit. Full story at AgFunderNews.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
She tells Fierce Pharma that drugmakers need new marketing playbooks, and Novo CEO Mike Doustdar explains the thinking behind the company's recent rebrand.
Pothier says social media and telehealth pulled GLP-1s partly out of doctors' hands, pushing Novo and Lilly to rethink launches. Novo CEO Mike Doustdar weighs in too.
Loading…